Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.
Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in …
Common Gynecologic Issues in Patients Post-Kidney Transplantation.
Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …
Peritoneal Hypoxia as a Gatekeeper Between Physiologic Retrograde Menstruation and Pathologic Persistence in Endometriosis.
Several hypotheses have been proposed to explain the establishment of endometriosis, of which retrograde menstruation remains the most widely accepted mechanism of dissemination. However, the mechanisms governing selective lesion establishment …